RSウイルス感染症治療薬の世界市場2016-2020...市場調査レポートについてご紹介

【英文タイトル】Global Human Respiratory Syncytial Virus Drugs Market 2016-2020

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

Table of Contents
PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Disease overview
• Understanding the disease
• Symptoms
• Causes
• Risk factors
• Complications
• Tests and diagnosis
• Key buying criteria

PART 06: Pipeline analysis

PART 07: Market landscape
• Global respiratory syncytial virus drugs market
• Five forces analysis

PART 08: Market segmentation by category of drug
• Approved Drugs
• Off-label drugs

PART 09: Geographical segmentation
• Human respiratory syncytial virus drugs market in US
• Human respiratory syncytial virus drugs market in Europe
• Human respiratory syncytial virus drugs market in ROW

PART 10: Market drivers
• Presence of large patient pool fuels market growth
• Launch of novel products
• Novel diagnostic tools increase patient population

PART 11: Impact of drivers

PART 12: Market challenges
• Continuous change in guidelines from healthcare organizations impacts market growth
• Cyclical nature of market hinders growth opportunities
• Limited drugs in market leading to low penetration rates

PART 13: Impact of drivers and challenges

PART 14: Market trends
• Emergence of new entrants likely to change market dynamics
• Growing strategic collaborations fostering innovation
• Active participation from emerging economies toward R&D

PART 15: Vendor landscape
• Competitive scenario

PART 16: Key vendor analysis
• AstraZeneca
• AbbVie
• GSK
• Teva Pharmaceutical
• Other prominent vendors

PART 17: Appendix
• List of abbreviations

PART 18: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Key customer segments of global human respiratory syncytial virus drugs market
Exhibit 03: Snapshot of RSV infection
Exhibit 04: Key buying criteria for RSV drugs
Exhibit 05: Factors affecting the adoption rates of RSV drugs
Exhibit 06: Pipeline analysis of key vendors in global human respiratory syncytial virus drugs market
Exhibit 07: Percentage share of drug candidates by stage of development
Exhibit 08: Pipeline candidates: Global human respiratory syncytial virus drugs market
Exhibit 09: Global human respiratory syncytial virus drugs market snapshot
Exhibit 10: Analysis of global human respiratory syncytial drugs market
Exhibit 11: Global human respiratory syncytial virus drugs market 2015-2020 ($ billions)
Exhibit 12: Emerging vendors and their initiatives
Exhibit 13: Opportunity analysis of global respiratory syncytial virus drugs market
Exhibit 14: Opportunity analysis in developed and emerging markets
Exhibit 15: Five forces analysis
Exhibit 16: Segmentation of global human respiratory syncytial virus drugs market by type of drug 2015
Exhibit 17: Segmentation of global human respiratory syncytial virus drugs market based on geography 2015 and 2020
Exhibit 18: Global human respiratory syncytial virus drugs market revenue by geography 2015-2020 ($ millions)
Exhibit 19: Incidence of RSV infections in US (on average every year)
Exhibit 20: Global human respiratory syncytial virus drugs market in US 2015-2020 ($ millions)
Exhibit 21: Key drivers and challenges in US
Exhibit 22: Human respiratory syncytial virus drugs market in Europe 2015-2020 ($ millions)
Exhibit 23: Trends in global human respiratory syncytial drugs market in Europe
Exhibit 24: Global human respiratory syncytial virus drugs market in ROW 2015-2020 ($ millions)
Exhibit 25: Key drivers and challenges in ROW
Exhibit 26: Trends in RSV epidemics
Exhibit 27: Potential products
Exhibit 28: Impact of drivers
Exhibit 29: Change in guidelines of AAPCID and its consequences
Exhibit 30: Impact of cyclical nature of RSV epidemics
Exhibit 31: Factors affecting penetration rates
Exhibit 32: Forcefield analysis of drivers and challenges in global human respiratory syncytial virus drugs market
Exhibit 33: Impact of drivers and challenges
Exhibit 34: Potential entrants
Exhibit 35: Strategic alliances
Exhibit 36: Competitive structure analysis of global human respiratory syncytial virus drugs market 2015
Exhibit 37: Market share analysis 2015
Exhibit 38: Market penetration of various RSV drug manufacturers in global human respiratory syncytial virus drugs market (2015)
Exhibit 39: Strategic success factors of companies in global human respiratory syncytial virus drugs market
Exhibit 40: AstraZeneca: Key highlights
Exhibit 41: AstraZeneca: Strength assessment
Exhibit 42: AstraZeneca: Strategy assessment
Exhibit 43: AstraZeneca: Opportunity assessment
Exhibit 44: AstraZeneca: Revenue of Synagis 2013-2015 ($ billions)
Exhibit 45: AstraZeneca: Geographic segmentation of Synagis 2015
Exhibit 46: AbbVie: Strength assessment
Exhibit 47: AbbVie: Strategy assessment
Exhibit 48: AbbVie: Opportunity assessment
Exhibit 49: AbbVie: Revenue of Synagis 2013-2015 ($ millions)
Exhibit 50: GSK: Profile
Exhibit 51: GSK: Strength assessment
Exhibit 52: GSK: Strategy assessment
Exhibit 53: GSK: Opportunity assessment
Exhibit 54: GSK: Revenue of Ventolin 2013-2015 ($ billions)
Exhibit 55: GSK: Geographical segmentation of Ventolin 2015
Exhibit 56: Teva Pharmaceutical: Profile
Exhibit 57: Teva Pharmaceutical: Strength assessment
Exhibit 58: Teva Pharmaceutical strategy assessment
Exhibit 59: Teva Pharmaceutical: Opportunity assessment
Exhibit 60: Teva Pharmaceuticals: YoY revenue and growth rate of ProAir 2013-2015 ($ millions)


【レポート販売概要】

■ タイトル:RSウイルス感染症治療薬の世界市場2016-2020
■ 英文:Global Human Respiratory Syncytial Virus Drugs Market 2016-2020
■ 発行日:2016年12月9日
■ 調査会社:Technavio
■ 商品コード:IRTNTR11070
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。